Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review

• Published in: International journal of molecular sciences 2024-04, Vol.25 (7), p.3717
• Main Authors: Plaza, Javier, Mínguez, Alejandro, Bastida, Guillermo, Marqués, Remedios, Nos, Pilar, Poveda, Jose Luis, Moret-Tatay, Inés
• Format: Article
• Language: English
• Subjects: Adalimumab; Analysis; anti-tumor necrosis factor; biological drugs; Biological products; Biomarkers; Care and treatment; Crohn's disease; Cytokines; Development and progression; Diarrhea; Drugs; Genetic aspects; Health aspects; Inflammatory bowel disease; infliximab; Microbiota; Missing data; Monoclonal antibodies; Pediatrics; Pharmacogenetics; Proteins; Single nucleotide polymorphisms; Systematic review; Tumor necrosis factor-TNF; Ulcerative colitis; ustekinumab
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25073717

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract usually characterized by diarrhea, rectal bleeding, and abdominal pain. IBD includes Crohn's disease and ulcerative colitis as the main entities. IBD is a debilitating condition that can lead to life-threatening complications, involving possible malignancy and surgery. The available therapies aim to achieve long-term remission and prevent disease progression. Biologics are bioengineered therapeutic drugs that mainly target proteins. Although they have revolutionized the treatment of IBD, their potential therapeutic benefits are limited due to large interindividual variability in clinical response in terms of efficacy and toxicity, resulting in high rates of long-term therapeutic failure. It is therefore important to find biomarkers that provide tailor-made treatment strategies that allow for patient stratification to maximize treatment benefits and minimize adverse events. Pharmacogenetics has the potential to optimize biologics selection in IBD by identifying genetic variants, specifically single nucleotide polymorphisms (SNPs), which are the underlying factors associated with an individual's drug response. This review analyzes the current knowledge of genetic variants associated with biological agent response (infliximab, adalimumab, ustekinumab, and vedolizumab) in IBD. An online literature search in various databases was conducted. After applying the inclusion and exclusion criteria, 28 reports from the 1685 results were employed for the review. The most significant SNPs potentially useful as predictive biomarkers of treatment response are linked to immunity, cytokine production, and immunorecognition.